| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-32 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
1997-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8569d6518d70c9cd50bcccb7ca24cd98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c467a62e9be5e16b26bd9a5633354d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90a8c09948a8fd371f0eff11885bd9e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7447874cca5e1592098d6884085f3157
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e39672900cf12ed562b3ace21bb26af9 |
| publicationDate |
1999-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
HU-9701778-A2 |
| titleOfInvention |
Use of raloxifene in the manufacture of a medicament for the prevention of breast cancer |
| abstract |
The present invention relates to a process for the use of ralolexifene or a pharmaceutically acceptable salt thereof in the manufacture of a medicament comprising the step of administering a dose of about 30 to about 150 mg / day of heat inhibits the development of breast cancer in these women. The process can be used in pharmacy. ŕ |
| priorityDate |
1996-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |